secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001193125-24-098509
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics prices upsized $150M public offering; provides preliminary cash of $162.8M
--------------------------------------------------------------------------------

- Pricing of 2,472,581 shares at $7.13/share and pre-funded warrants for 18,577,419 shares at $7.1299/warrant.
- Gross proceeds ~$150.1M; net proceeds ~$144.7M (or ~$165.9M if underwriters exercise overallotment for 3,157,500 additional shares).
- Cash, cash equivalents and marketable securities of $162.8M as of March 31, 2024 (preliminary, unaudited).
- Proceeds expected to fund operations into Q4 2026; use for general corporate purposes.
- Offering expected to close April 19, 2024; Morgan Stanley and TD Cowen joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524098509/0001193125-24-098509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524098509/d816959d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-098509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer